EYENOVIA INC (EYEN) Stock Price & Overview

NASDAQ:EYEN • US30234E2037

15.82 USD
+5.26 (+49.81%)
At close: Jul 2, 2025
15.9 USD
+0.08 (+0.51%)
After Hours: 7/2/2025, 8:00:02 PM

The current stock price of EYEN is 15.82 USD. Today EYEN is up by 49.81%. In the past month the price increased by 649.76%. In the past year, price decreased by -77.32%.

EYEN Key Statistics

52-Week Range0.85 - 124.8
Current EYEN stock price positioned within its 52-week range.
1-Month Range1.89 - 17.18
Current EYEN stock price positioned within its 1-month range.
Market Cap
80.682M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-34.16
Dividend Yield
N/A

EYEN Stock Performance

Today
+49.81%
1 Week
+65.65%
1 Month
+649.76%
3 Months
+1,547.75%
Longer-term
6 Months +79.61%
1 Year -77.32%
2 Years -90.72%
3 Years -88.37%
5 Years -94.38%
10 Years N/A

EYEN Stock Chart

EYENOVIA INC / EYEN Daily stock chart

EYEN Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to EYEN. When comparing the yearly performance of all stocks, EYEN is one of the better performing stocks in the market, outperforming 99.78% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
EYEN Full Technical Analysis Report

EYEN Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to EYEN. EYEN has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
EYEN Full Fundamental Analysis Report

EYEN Earnings

On May 19, 2025 EYEN reported an EPS of -1.63 and a revenue of 15.00K. The company beat EPS expectations (83.35% surprise) and missed revenue expectations (-96.32% surprise).

Next Earnings DateAug 11, 2025
Last Earnings DateMay 19, 2025
PeriodQ1 / 2025
EPS Reported-$1.63
Revenue Reported15K
EPS Surprise 83.35%
Revenue Surprise -96.32%
EYEN Earnings History

EYEN Forecast & Estimates

8 analysts have analysed EYEN and the average price target is 163.2 USD. This implies a price increase of 931.61% is expected in the next year compared to the current price of 15.82.

For the next year, analysts expect an EPS growth of 33.51% and a revenue growth 400.98% for EYEN


Analysts
Analysts47.5
Price Target163.2 (931.61%)
EPS Next Y33.51%
Revenue Next Year400.98%
EYEN Forecast & Estimates

EYEN Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

EYEN Financial Highlights

Over the last trailing twelve months EYEN reported a non-GAAP Earnings per Share(EPS) of -34.16. The EPS increased by 43.07% compared to the year before.


Income Statements
Revenue(TTM)67.00K
Net Income(TTM)-42.38M
Industry RankSector Rank
PM (TTM) N/A
ROA -708.22%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%91.14%
Sales Q2Q%275%
EPS 1Y (TTM)43.07%
Revenue 1Y (TTM)781.58%
EYEN financials

EYEN Ownership

Ownership
Inst Owners9.67%
Shares5.10M
Float5.08M
Ins Owners0.74%
Short Float %N/A
Short RatioN/A
EYEN Ownership

EYEN Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO28.36921.899B
JNJ JOHNSON & JOHNSON20.93583.292B
MRK MERCK & CO. INC.22.54286.575B
PFE PFIZER INC8.97152.733B
BMY BRISTOL-MYERS SQUIBB CO9.36120.05B
ZTS ZOETIS INC16.3448.739B
RPRX ROYALTY PHARMA PLC- CL A8.8926.461B
VTRS VIATRIS INC5.515.889B
ELAN ELANCO ANIMAL HEALTH INC21.7211.276B
AXSM AXSOME THERAPEUTICS INC N/A7.883B
BLTE BELITE BIO INC - ADR N/A6.361B
TERN TERNS PHARMACEUTICALS INC N/A4.698B
LGND LIGAND PHARMACEUTICALS23.984.217B

About EYEN

Company Profile

EYEN logo image Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The company is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.

Company Info

IPO: 2018-01-25

EYENOVIA INC

295 Madison Ave Ste 2400

New York City NEW YORK 10017 US

CEO: Tsontcho Ianchulev

Employees: 14

EYEN Company Website

EYEN Investor Relations

Phone: 18137669539

EYENOVIA INC / EYEN FAQ

Can you describe the business of EYENOVIA INC?

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The company is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.


Can you provide the latest stock price for EYENOVIA INC?

The current stock price of EYEN is 15.82 USD. The price increased by 49.81% in the last trading session.


Does EYEN stock pay dividends?

EYEN does not pay a dividend.


How is the ChartMill rating for EYENOVIA INC?

EYEN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


How many employees does EYENOVIA INC have?

EYENOVIA INC (EYEN) currently has 14 employees.


Can you provide the market cap for EYENOVIA INC?

EYENOVIA INC (EYEN) has a market capitalization of 80.68M USD. This makes EYEN a Micro Cap stock.